摘要
I will have a couple of comments on the issues elaborated in the article titled as‘Impact of COVID-19 in patients with lymphoid malignancies’.First,the author did not emphasize and overlook the prolonged persistence of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)RNA in coronavirus disease 2019(COVID-19)patients with hematological malignancies.Second,the rise of a chronic lymphoid leukemia clone in COVID-19 was not mentioned by the authors.Third,achieving a complete remission in asymptomatic COVID-19 patients with follicular lymphoma in partial remission after bendamustine-based therapy is not specific to this lymphoma subtype.Fourth,follicular lymphoma does not always undergo complete remission with SARS-CoV-2 infection.Our aim is to help the authors to discuss and clarify these issues a little more in COVID-19 patients with hematological malignancies.
